What Is EW Fair Value?
Edwards Lifesciences (EW) fair value estimate using multiple valuation models, updated daily.
As of October 14, 2026, Edwards Lifesciences (EW) has a composite fair value estimate of $60.69 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $85.27, suggesting the stock is overvalued by 28.8%.
Data as of October 14, 2026 (today)
Composite Fair Value
Overvalued3 of 4 models$60.69
vs. current price of $85.27(-28.8%)
How Is EW Fair Value Calculated?
Four independent models estimate what EW is worth. Each uses different inputs and assumptions. The composite blends them by weight.
EW Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
41% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$76.60
-10.2%Fair Value
Inputs used
DDM (Dividend Discount Model)
0% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
N/A
This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.
EW Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
29% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$35.25
-58.7%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
29% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$44.94
-47.3%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $85.27 is 10.2% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $1.42B | $1.30B |
| Year 2 | $1.63B | $1.37B |
| Year 3 | $1.87B | $1.44B |
| Year 4 | $2.15B | $1.52B |
| Year 5 | $2.48B | $1.60B |
| Year 6 | $2.85B | $1.68B |
| Year 7 | $3.28B | $1.77B |
| Year 8 | $3.77B | $1.87B |
| Year 9 | $4.33B | $1.96B |
| Year 10 | $4.98B | $2.07B |
| Terminal Value | $76.44B | $31.77B |
What Are EW's Key Financial Metrics?
Earnings & Growth
Current Price
$85.27
EPS (TTM)
$1.68
Forward P/E
25.2
Profit Margin
15.4%
Cash & Balance Sheet
Free Cash Flow
1.2B
EBITDA
2B
Book Value
$18.42
Total Debt
704.4M
What Do Analysts Say About EW?
Low
$84.00
Average
$101.96
High
$110.00
Upside
+19.6%
EW Fair Value FAQ
What is the fair value of EW?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), EW's estimated fair value is $60.69. The stock is currently trading at $85.27, which makes it overvalued by our analysis.
How is EW's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is EW overvalued or undervalued?
Based on our analysis, EW is overvalued. The current price of $85.27 is 28.8% above our estimated fair value of $60.69.
What do Wall Street analysts say about EW?
26 analysts cover Edwards Lifesciences with a consensus rating of "Buy." The average price target is $101.96, ranging from $84.00 to $110.00. This implies 19.6% upside from the current price.